Diabetes

A free online program called Fit2Me allows T2D patients to tailor 4 key areas of diabetes care to their specific needs

Adlyxin maintains normal A1c levels in patients with type 2 diabetes.

Adlyxin is a once-daily injection that improves glycemic control in type 2 diabetes.

The FDA has just approved Sanofi's lixisenatide (Adlyxin), a new glucagon-like peptide-1 (GLP-1) receptor agonist to improve glycemic control, in conjunction with diet and exercise, in adults with type 2 diabetes.

An FDA advisory panel recently gave the green light for a hemoglobin A1C test to diagnose diabetes in certain care settings.

Researchers were unable to find a strong link between diabetes drugs and cardiovascular mortality.

Study finds global need for health care interventions that target diabetes.

When a patient begins using insulin to manage diabetes, the initial dose is just a starting point.

Obese patients typically require higher doses of insulin therapy.

Study evaluates the association between consuming butter and the development of diabetes and other chronic diseases.

The FDA has approved an expanded indication for type 2 diabetes treatment Synjardy (empagliflozin and metformin hydrochloride) to include treatment-naïve adults. Synjardy is designed to improve glycemic control in adults with type 2 diabetes.

Synjardy expanded to include treatment naïve adults with type 2 diabetes.

Surveys show patients more willing to seek more aggressive treatment than physicians realize.

The Diabetes Prevention Program is the first prevention program to expand from CMS Innovation Center to Medicare.

Surprising findings on the relationship between obesity, type 2 diabetes, and dementia.

Top news of the day from across the health care landscape.

In addition to weight gain and poor diet quality, eating meals outside the home has been linked with a greater risk of developing type 2 diabetes.

Benign meningioma tumors may be less likely in patients with high blood sugar.

More than 30 national health care decision-makers have gathered outside of the Nation's Capital this week for an Academy of Managed Care Pharmacy event focusing on innovations in diabetes care that are producing changes to treatment options, patient engagement, accountability and patient-provider interactions.

Liraglutide found to lower the overall risk of stroke and heart attack.

Although longer needles are often prescribed for patients with increased body fat, this practice actually has no clinical basis.

Regular physical activity is effective lowering the risk of diabetes, but some patients do not see improved insulin sensitivity.

The FDA has approved a dedicated syringe for Humulin R U-500 insulin, eliminating the need for dose conversions for patients who previously used U-100 tuberculin syringes.

Women averaging 60-hour work weeks found to be at greater risk for a number of chronic diseases.